首页 > 最新文献

Alzheimer's Research & Therapy最新文献

英文 中文
Comparison of subjective cognitive decline and polygenic risk score in the prediction of all-cause dementia, Alzheimer's disease and vascular dementia. 主观认知能力下降与多基因风险评分在预测全因痴呆症、阿尔茨海默病和血管性痴呆症方面的比较。
IF 7.9 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-08-19 DOI: 10.1186/s13195-024-01559-9
Kira Trares, Hannah Stocker, Joshua Stevenson-Hoare, Laura Perna, Bernd Holleczek, Konrad Beyreuther, Ben Schöttker, Hermann Brenner

Background: Polygenic risk scores (PRS) and subjective cognitive decline (SCD) are associated with the risk of developing dementia. It remains to examine whether they can improve the established cardiovascular risk factors aging and dementia (CAIDE) model and how their predictive abilities compare.

Methods: The CAIDE model was applied to a sub-sample of a large, population-based cohort study (n = 5,360; aged 50-75) and evaluated for the outcomes of all-cause dementia, Alzheimer's disease (AD) and vascular dementia (VD) by calculating Akaike's information criterion (AIC) and the area under the curve (AUC). The improvement of the CAIDE model by PRS and SCD was further examined using the net reclassification improvement (NRI) method and integrated discrimination improvement (IDI).

Results: During 17 years of follow-up, 410 participants were diagnosed with dementia, including 139 AD and 152 VD diagnoses. Overall, the CAIDE model showed high discriminative ability for all outcomes, reaching AUCs of 0.785, 0.793, and 0.789 for all-cause dementia, AD, and VD, respectively. Adding information on SCD significantly increased NRI for all-cause dementia (4.4%, p = 0.04) and VD (7.7%, p = 0.01). In contrast, prediction models for AD further improved when PRS was added to the model (NRI, 8.4%, p = 0.03). When APOE ε4 carrier status was included (CAIDE Model 2), AUCs increased, but PRS and SCD did not further improve the prediction.

Conclusions: Unlike PRS, information on SCD can be assessed more efficiently, and thus, the model including SCD can be more easily transferred to the clinical setting. Nevertheless, the two variables seem negligible if APOE ε4 carrier status is available.

背景:多基因风险评分(PRS)和主观认知能力下降(SCD)与痴呆症的发病风险有关。我们仍需研究它们是否能改善已建立的心血管风险因素老龄化与痴呆(CAIDE)模型,以及它们的预测能力如何比较:将 CAIDE 模型应用于一项大型人群队列研究的子样本(n = 5,360;年龄 50-75 岁),并通过计算 Akaike 信息标准(AIC)和曲线下面积(AUC)对全因痴呆、阿尔茨海默病(AD)和血管性痴呆(VD)的结果进行评估。使用净重分类改进(NRI)法和综合辨别改进(IDI)法进一步检验了PRS和SCD对CAIDE模型的改进:在17年的随访中,410名参与者被诊断为痴呆症,其中139人被诊断为AD,152人被诊断为VD。总体而言,CAIDE模型对所有结果都显示出较高的判别能力,对全因痴呆、AD和VD的AUC分别达到0.785、0.793和0.789。添加 SCD 信息后,全因痴呆(4.4%,p = 0.04)和 VD(7.7%,p = 0.01)的 NRI 明显增加。与此相反,在模型中加入 PRS 后,AD 预测模型得到了进一步改善(NRI,8.4%,p = 0.03)。当加入 APOE ε4 携带者状态时(CAIDE 模型 2),AUCs 增加,但 PRS 和 SCD 并未进一步改善预测:结论:与 PRS 不同,SCD 的信息可以更有效地评估,因此包含 SCD 的模型更容易应用于临床。尽管如此,如果有 APOE ε4 携带者身份,这两个变量似乎可以忽略不计。
{"title":"Comparison of subjective cognitive decline and polygenic risk score in the prediction of all-cause dementia, Alzheimer's disease and vascular dementia.","authors":"Kira Trares, Hannah Stocker, Joshua Stevenson-Hoare, Laura Perna, Bernd Holleczek, Konrad Beyreuther, Ben Schöttker, Hermann Brenner","doi":"10.1186/s13195-024-01559-9","DOIUrl":"10.1186/s13195-024-01559-9","url":null,"abstract":"<p><strong>Background: </strong>Polygenic risk scores (PRS) and subjective cognitive decline (SCD) are associated with the risk of developing dementia. It remains to examine whether they can improve the established cardiovascular risk factors aging and dementia (CAIDE) model and how their predictive abilities compare.</p><p><strong>Methods: </strong>The CAIDE model was applied to a sub-sample of a large, population-based cohort study (n = 5,360; aged 50-75) and evaluated for the outcomes of all-cause dementia, Alzheimer's disease (AD) and vascular dementia (VD) by calculating Akaike's information criterion (AIC) and the area under the curve (AUC). The improvement of the CAIDE model by PRS and SCD was further examined using the net reclassification improvement (NRI) method and integrated discrimination improvement (IDI).</p><p><strong>Results: </strong>During 17 years of follow-up, 410 participants were diagnosed with dementia, including 139 AD and 152 VD diagnoses. Overall, the CAIDE model showed high discriminative ability for all outcomes, reaching AUCs of 0.785, 0.793, and 0.789 for all-cause dementia, AD, and VD, respectively. Adding information on SCD significantly increased NRI for all-cause dementia (4.4%, p = 0.04) and VD (7.7%, p = 0.01). In contrast, prediction models for AD further improved when PRS was added to the model (NRI, 8.4%, p = 0.03). When APOE ε4 carrier status was included (CAIDE Model 2), AUCs increased, but PRS and SCD did not further improve the prediction.</p><p><strong>Conclusions: </strong>Unlike PRS, information on SCD can be assessed more efficiently, and thus, the model including SCD can be more easily transferred to the clinical setting. Nevertheless, the two variables seem negligible if APOE ε4 carrier status is available.</p>","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":null,"pages":null},"PeriodicalIF":7.9,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11331600/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142003383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of strategic white matter hyperintensities of cholinergic pathways on basal forebrain volume in patients with amyloid-negative neurocognitive disorders. 淀粉样蛋白阴性神经认知障碍患者胆碱能通路策略性白质高密度对前脑基底体积的影响。
IF 7.9 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-08-15 DOI: 10.1186/s13195-024-01536-2
Ye Eun Kim, Jae-Sung Lim, Chong Hyun Suh, Hwon Heo, Jee Hoon Roh, E-Nae Cheong, Yoojin Lee, Jae Woo Kim, Jae-Hong Lee

Background: The cholinergic neurotransmitter system is crucial to cognitive function, with the basal forebrain (BF) being particularly susceptible to Alzheimer's disease (AD) pathology. However, the interaction of white matter hyperintensities (WMH) in cholinergic pathways and BF atrophy without amyloid pathology remains poorly understood.

Methods: We enrolled patients who underwent neuropsychological tests, magnetic resonance imaging, and 18F-florbetaben positron emission tomography due to cognitive impairment at the teaching university hospital from 2015 to 2022. Among these, we selected patients with negative amyloid scans and additionally excluded those with Parkinson's dementia that may be accompanied by BF atrophy. The WMH burden of cholinergic pathways was quantified by the Cholinergic Pathways Hyperintensities Scale (CHIPS) score, and categorized into tertile groups because the CHIPS score did not meet normal distribution. Segmentation of the BF on volumetric T1-weighted MRI was performed using FreeSurfer, then was normalized for total intracranial volume. Multivariable regression analysis was performed to investigate the association between BF volumes and CHIPS scores.

Results: A total of 187 patients were enrolled. The median CHIPS score was 12 [IQR 5.0; 24.0]. The BF volume of the highest CHIPS tertile group (mean ± SD, 3.51 ± 0.49, CHIPSt3) was significantly decreased than those of the lower CHIPS tertile groups (3.75 ± 0.53, CHIPSt2; 3.83 ± 0.53, CHIPSt1; P = 0.02). In the univariable regression analysis, factors showing significant associations with the BF volume were the CHIPSt3 group, age, female, education, diabetes mellitus, smoking, previous stroke history, periventricular WMH, and cerebral microbleeds. In multivariable regression analysis, the CHIPSt3 group (standardized beta [βstd] = -0.25, P = 0.01), female (βstd = 0.20, P = 0.04), and diabetes mellitus (βstd = -0.22, P < 0.01) showed a significant association with the BF volume. Sensitivity analyses showed a negative correlation between CHIPS score and normalized BF volume, regardless of WMH severity.

Conclusions: We identified a significant correlation between strategic WMH burden in the cholinergic pathway and BF atrophy independently of amyloid positivity and WMH severity. These results suggest a mechanism of cholinergic neuronal loss through the dying-back phenomenon and provide a rationale that strategic WMH assessment may help identify target groups that may benefit from acetylcholinesterase inhibitor treatment.

背景:胆碱能神经递质系统对认知功能至关重要:胆碱能神经递质系统对认知功能至关重要,而基底前脑(BF)尤其容易受到阿尔茨海默病(AD)病理学的影响。然而,人们对胆碱能通路中的白质高密度(WMH)与无淀粉样病变的前脑基底层萎缩之间的相互作用仍然知之甚少:我们招募了2015年至2022年期间在大学教学医院因认知障碍而接受神经心理学测试、磁共振成像和18F-氟贝特宾正电子发射断层扫描的患者。在这些患者中,我们选择了淀粉样蛋白扫描阴性的患者,并排除了可能伴有BF萎缩的帕金森痴呆患者。胆碱能通路高密度量表(CHIPS)评分量化了胆碱能通路的WMH负担,由于CHIPS评分不符合正态分布,因此将其分为三等分组。使用FreeSurfer对T1加权磁共振成像上的BF进行分割,然后根据颅内总容积进行归一化处理。为了研究BF体积与CHIPS评分之间的关系,进行了多变量回归分析:共有 187 名患者入选。CHIPS评分的中位数为12 [IQR 5.0; 24.0]。CHIPS 三等分最高组的 BF 容量(平均值 ± SD,3.51 ± 0.49,CHIPSt3)明显低于 CHIPS 三等分较低组(3.75 ± 0.53,CHIPSt2;3.83 ± 0.53,CHIPSt1;P = 0.02)。在单变量回归分析中,CHIPSt3 组、年龄、女性、教育程度、糖尿病、吸烟、既往中风史、脑室周围 WMH 和脑微小出血等因素与 BF 容量有显著相关性。在多变量回归分析中,CHIPSt3 组(标准化贝塔值[βstd] = -0.25,P = 0.01)、女性(βstd = 0.20,P = 0.04)和糖尿病(βstd = -0.22,P 结论:CHIPSt3 组与糖尿病组之间存在显著的相关性:我们发现胆碱能通路中的战略性 WMH 负荷与 BF 萎缩之间存在明显的相关性,而与淀粉样蛋白阳性率和 WMH 严重程度无关。这些结果表明,胆碱能神经元损失的机制是凋亡-回缩现象,并为策略性 WMH 评估提供了理论依据,有助于确定可从乙酰胆碱酯酶抑制剂治疗中获益的目标群体。
{"title":"Effects of strategic white matter hyperintensities of cholinergic pathways on basal forebrain volume in patients with amyloid-negative neurocognitive disorders.","authors":"Ye Eun Kim, Jae-Sung Lim, Chong Hyun Suh, Hwon Heo, Jee Hoon Roh, E-Nae Cheong, Yoojin Lee, Jae Woo Kim, Jae-Hong Lee","doi":"10.1186/s13195-024-01536-2","DOIUrl":"10.1186/s13195-024-01536-2","url":null,"abstract":"<p><strong>Background: </strong>The cholinergic neurotransmitter system is crucial to cognitive function, with the basal forebrain (BF) being particularly susceptible to Alzheimer's disease (AD) pathology. However, the interaction of white matter hyperintensities (WMH) in cholinergic pathways and BF atrophy without amyloid pathology remains poorly understood.</p><p><strong>Methods: </strong>We enrolled patients who underwent neuropsychological tests, magnetic resonance imaging, and <sup>18</sup>F-florbetaben positron emission tomography due to cognitive impairment at the teaching university hospital from 2015 to 2022. Among these, we selected patients with negative amyloid scans and additionally excluded those with Parkinson's dementia that may be accompanied by BF atrophy. The WMH burden of cholinergic pathways was quantified by the Cholinergic Pathways Hyperintensities Scale (CHIPS) score, and categorized into tertile groups because the CHIPS score did not meet normal distribution. Segmentation of the BF on volumetric T1-weighted MRI was performed using FreeSurfer, then was normalized for total intracranial volume. Multivariable regression analysis was performed to investigate the association between BF volumes and CHIPS scores.</p><p><strong>Results: </strong>A total of 187 patients were enrolled. The median CHIPS score was 12 [IQR 5.0; 24.0]. The BF volume of the highest CHIPS tertile group (mean ± SD, 3.51 ± 0.49, CHIPSt3) was significantly decreased than those of the lower CHIPS tertile groups (3.75 ± 0.53, CHIPSt2; 3.83 ± 0.53, CHIPSt1; P = 0.02). In the univariable regression analysis, factors showing significant associations with the BF volume were the CHIPSt3 group, age, female, education, diabetes mellitus, smoking, previous stroke history, periventricular WMH, and cerebral microbleeds. In multivariable regression analysis, the CHIPSt3 group (standardized beta [β<sub>std</sub>] = -0.25, P = 0.01), female (β<sub>std</sub> = 0.20, P = 0.04), and diabetes mellitus (β<sub>std</sub> = -0.22, P < 0.01) showed a significant association with the BF volume. Sensitivity analyses showed a negative correlation between CHIPS score and normalized BF volume, regardless of WMH severity.</p><p><strong>Conclusions: </strong>We identified a significant correlation between strategic WMH burden in the cholinergic pathway and BF atrophy independently of amyloid positivity and WMH severity. These results suggest a mechanism of cholinergic neuronal loss through the dying-back phenomenon and provide a rationale that strategic WMH assessment may help identify target groups that may benefit from acetylcholinesterase inhibitor treatment.</p>","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":null,"pages":null},"PeriodicalIF":7.9,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11325579/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141987231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Herpes zoster and long-term risk of subjective cognitive decline. 带状疱疹与主观认知能力下降的长期风险。
IF 7.9 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-08-14 DOI: 10.1186/s13195-024-01511-x
Tian-Shin Yeh, Gary C Curhan, Barbara P Yawn, Walter C Willett, Sharon G Curhan

Background: Herpes zoster (HZ), commonly known as "shingles," may contribute to cognitive decline through mechanisms such as neuroinflammation or direct neuronal injury. However, evidence on the longitudinal association between HZ and cognitive decline is conflicting and whether the risk differs by APOE ε4-carrier status has not been studied; prospective cohort studies on the association between HZ vaccination and cognitive decline are also lacking.

Methods: We included 149,327 participants from three large cohorts-the Nurses' Health Study (NHS), NHSII, and Health Professionals Follow-Up Study (HPFS)-to prospectively examine the association between HZ and subsequent subjective cognitive decline (SCD). Poisson regression was used to estimate the multivariable-adjusted relative risk (MVRR) of a 3-unit increment in SCD score according to years since HZ compared with participants with no history of HZ.

Results: Compared with individuals with no history of HZ, the MVRR (95% CI) of a 3-unit increment in SCD score was significantly and independently higher among individuals with a history of HZ, but the duration of time since HZ when the elevated risk of SCD was statistically significant differed among the cohorts. In NHS, HZ was associated with higher long-term risk of SCD; compared with individuals with no history of HZ, the MVRR (95% CI) of a 3-unit increment in SCD score was 1.14 (1.01, 1.32) for ≥ 13 years since HZ. In NHS II, HZ was associated with higher risk of SCD in both the short-term [MVRR 1.34 (1.18, 1.53) for 1-4 years] and long-term [MVRR 1.20 (1.08, 1.34) for ≥ 13 years since HZ]. In HPFS, an elevated risk of SCD was suggested across all time points. Among the subset of participants with information on APOE ε4, there was a suggestion that the association differed by APOE ε4 carrier status, but the results were not consistent between women and men. Among the subset of women with information on HZ vaccination, there was a suggestion that the long-term risk of SCD may be greater among women who were not vaccinated against HZ.

Conclusions: Data from three large independent cohorts of women and men showed that HZ was associated with higher long-term risk of SCD, and the risk may differ by APOE ε4-carrier status.

背景:带状疱疹(HZ),俗称 "带状疱疹",可能通过神经炎症或直接神经元损伤等机制导致认知能力下降。然而,关于 HZ 与认知能力下降之间的纵向关系的证据并不一致,而且尚未研究 APOE ε4 携带者的身份是否会导致不同的风险;也缺乏关于 HZ 疫苗接种与认知能力下降之间关系的前瞻性队列研究:我们纳入了来自三个大型队列--护士健康研究(NHS)、NHSII和卫生专业人员随访研究(HPFS)--的149327名参与者,以前瞻性地研究HZ与随后的主观认知能力下降(SCD)之间的关系。与无 HZ 病史的参与者相比,我们采用泊松回归法估算了根据 HZ 发生年限 SCD 得分每增加 3 个单位的多变量调整相对风险 (MVRR):与无 HZ 病史者相比,有 HZ 病史者的 SCD 评分每增加 3 个单位的 MVRR(95% CI)显著且独立地高于无 HZ 病史者。在 NHS 中,HZ 与较高的 SCD 长期风险相关;与无 HZ 史的个体相比,HZ 发生时间≥ 13 年时,SCD 评分每增加 3 个单位的 MVRR(95% CI)为 1.14(1.01,1.32)。在 NHS II 中,HZ 与较高的短期 SCD 风险[1-4 年的 MVRR 为 1.34 (1.18, 1.53)]和长期 SCD 风险[HZ 后≥ 13 年的 MVRR 为 1.20 (1.08, 1.34)]相关。在 HPFS 中,所有时间点的 SCD 风险均升高。在有 APOE ε4 相关信息的参与者子集中,APOE ε4携带者状态不同,相关性也不同,但男女之间的结果并不一致。在有HZ疫苗接种信息的女性子集中,有迹象表明未接种HZ疫苗的女性患SCD的长期风险可能更大:来自三个大型女性和男性独立队列的数据显示,HZ与较高的SCD长期风险相关,且风险可能因APOE ε4携带者身份而异。
{"title":"Herpes zoster and long-term risk of subjective cognitive decline.","authors":"Tian-Shin Yeh, Gary C Curhan, Barbara P Yawn, Walter C Willett, Sharon G Curhan","doi":"10.1186/s13195-024-01511-x","DOIUrl":"10.1186/s13195-024-01511-x","url":null,"abstract":"<p><strong>Background: </strong>Herpes zoster (HZ), commonly known as \"shingles,\" may contribute to cognitive decline through mechanisms such as neuroinflammation or direct neuronal injury. However, evidence on the longitudinal association between HZ and cognitive decline is conflicting and whether the risk differs by APOE ε4-carrier status has not been studied; prospective cohort studies on the association between HZ vaccination and cognitive decline are also lacking.</p><p><strong>Methods: </strong>We included 149,327 participants from three large cohorts-the Nurses' Health Study (NHS), NHSII, and Health Professionals Follow-Up Study (HPFS)-to prospectively examine the association between HZ and subsequent subjective cognitive decline (SCD). Poisson regression was used to estimate the multivariable-adjusted relative risk (MVRR) of a 3-unit increment in SCD score according to years since HZ compared with participants with no history of HZ.</p><p><strong>Results: </strong>Compared with individuals with no history of HZ, the MVRR (95% CI) of a 3-unit increment in SCD score was significantly and independently higher among individuals with a history of HZ, but the duration of time since HZ when the elevated risk of SCD was statistically significant differed among the cohorts. In NHS, HZ was associated with higher long-term risk of SCD; compared with individuals with no history of HZ, the MVRR (95% CI) of a 3-unit increment in SCD score was 1.14 (1.01, 1.32) for ≥ 13 years since HZ. In NHS II, HZ was associated with higher risk of SCD in both the short-term [MVRR 1.34 (1.18, 1.53) for 1-4 years] and long-term [MVRR 1.20 (1.08, 1.34) for ≥ 13 years since HZ]. In HPFS, an elevated risk of SCD was suggested across all time points. Among the subset of participants with information on APOE ε4, there was a suggestion that the association differed by APOE ε4 carrier status, but the results were not consistent between women and men. Among the subset of women with information on HZ vaccination, there was a suggestion that the long-term risk of SCD may be greater among women who were not vaccinated against HZ.</p><p><strong>Conclusions: </strong>Data from three large independent cohorts of women and men showed that HZ was associated with higher long-term risk of SCD, and the risk may differ by APOE ε4-carrier status.</p>","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":null,"pages":null},"PeriodicalIF":7.9,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11323373/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141974837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Plasma lipidomics in early APP/PS1 female mouse model and its relationship with brain: Is it affected by the estrous cycle? 早期APP/PS1雌性小鼠血浆脂质组学及其与大脑的关系:它受发情周期的影响吗?
IF 7.9 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-08-14 DOI: 10.1186/s13195-024-01549-x
Laura Ferré-González, Ángel Balaguer, Marta Roca, Artemis Ftara, Ana Lloret, Consuelo Cháfer-Pericás

Background: Alzheimer's disease (AD) is the most prevalent dementia, showing higher incidence in women. Besides, lipids play an essential role in brain, and they could be dysregulated in neurodegeneration. Specifically, impaired plasma lipid levels could predict early AD diagnosis. This work aims to identify the main plasma lipids altered in early AD female mouse model and evaluate their relationship with brain lipidome. Also, the possible involvement of the estrous cycle in lipid metabolism has been evaluated.

Methods: Plasma samples of wild-type (n = 10) and APP/PS1 (n = 10) female mice of 5 months of age were collected, processed, and analysed using a lipidomic mass spectrometry-based method. A statistical analysis involving univariate and multivariate approaches was performed to identify significant lipid differences related to AD between groups. Also, cytology tests were conducted to confirm estrous cycle phases.

Results: Three hundred thirty lipids were detected in plasma, 18 of them showed significant differences between groups; specifically, some triacylglycerols, cholesteryl esters, lysophosphatidylcholines, phosphatidylcholines, and ether-linked phosphatidylcholines, increased in early AD; while other phosphatidylcholines, phosphatidylethanolamines, ceramides, and ether-linked phosphatidylethanolamines decreased in early AD. A multivariate approach was developed from some lipid variables, showing high diagnostic indexes (70% sensitivity, 90% specificity, 80% accuracy). From brain and plasma lipidome, some significant correlations were observed, mainly in the glycerophospholipid family. Also, some differences were found in both plasma and brain lipids, according to the estrous cycle phase.

Conclusions: Therefore, lipid alterations can be identified in plasma at early AD stages in mice females, with a relationship with brain lipid metabolism for most of the lipid subfamilies, suggesting some lipids as potential AD biomarkers. In addition, the estrous cycle monitoring could be relevant in female studies.

背景:阿尔茨海默病(AD)是最常见的痴呆症,女性发病率较高。此外,血脂在大脑中扮演着重要角色,在神经退行性病变中可能出现失调。具体来说,血浆脂质水平受损可预测早期老年痴呆症的诊断。本研究旨在确定早期AD雌性小鼠模型中发生改变的主要血浆脂质,并评估它们与脑脂质组的关系。此外,还对发情周期可能参与脂质代谢进行了评估:方法:收集、处理和分析5月龄野生型(n = 10)和APP/PS1(n = 10)雌性小鼠的血浆样本,采用基于脂质体质谱的方法进行分析。采用单变量和多变量方法进行统计分析,以确定各组间与AD相关的显著脂质差异。此外,还进行了细胞学检测以确认发情周期阶段:结果:血浆中检测出 3300 种脂质,其中 18 种脂质在组间存在显著差异;具体而言,一些三酰甘油、胆固醇酯、溶血磷脂酰胆碱、磷脂酰胆碱和醚键磷脂酰胆碱在 AD 早期升高;而其他磷脂酰胆碱、磷脂酰乙醇胺、神经酰胺和醚键磷脂酰乙醇胺在 AD 早期降低。根据一些脂质变量开发的多变量方法显示出较高的诊断指数(灵敏度 70%、特异度 90%、准确度 80%)。从大脑和血浆脂质组中观察到了一些显著的相关性,主要是在甘油磷脂家族中。此外,根据发情周期阶段的不同,血浆和大脑脂质也存在一些差异:因此,在小鼠雌性AD的早期阶段,可以发现血浆中的脂质发生了改变,大多数脂质亚族与脑脂质代谢有关,这表明一些脂质可能是AD的生物标志物。此外,发情周期监测可能与雌性研究相关。
{"title":"Plasma lipidomics in early APP/PS1 female mouse model and its relationship with brain: Is it affected by the estrous cycle?","authors":"Laura Ferré-González, Ángel Balaguer, Marta Roca, Artemis Ftara, Ana Lloret, Consuelo Cháfer-Pericás","doi":"10.1186/s13195-024-01549-x","DOIUrl":"10.1186/s13195-024-01549-x","url":null,"abstract":"<p><strong>Background: </strong>Alzheimer's disease (AD) is the most prevalent dementia, showing higher incidence in women. Besides, lipids play an essential role in brain, and they could be dysregulated in neurodegeneration. Specifically, impaired plasma lipid levels could predict early AD diagnosis. This work aims to identify the main plasma lipids altered in early AD female mouse model and evaluate their relationship with brain lipidome. Also, the possible involvement of the estrous cycle in lipid metabolism has been evaluated.</p><p><strong>Methods: </strong>Plasma samples of wild-type (n = 10) and APP/PS1 (n = 10) female mice of 5 months of age were collected, processed, and analysed using a lipidomic mass spectrometry-based method. A statistical analysis involving univariate and multivariate approaches was performed to identify significant lipid differences related to AD between groups. Also, cytology tests were conducted to confirm estrous cycle phases.</p><p><strong>Results: </strong>Three hundred thirty lipids were detected in plasma, 18 of them showed significant differences between groups; specifically, some triacylglycerols, cholesteryl esters, lysophosphatidylcholines, phosphatidylcholines, and ether-linked phosphatidylcholines, increased in early AD; while other phosphatidylcholines, phosphatidylethanolamines, ceramides, and ether-linked phosphatidylethanolamines decreased in early AD. A multivariate approach was developed from some lipid variables, showing high diagnostic indexes (70% sensitivity, 90% specificity, 80% accuracy). From brain and plasma lipidome, some significant correlations were observed, mainly in the glycerophospholipid family. Also, some differences were found in both plasma and brain lipids, according to the estrous cycle phase.</p><p><strong>Conclusions: </strong>Therefore, lipid alterations can be identified in plasma at early AD stages in mice females, with a relationship with brain lipid metabolism for most of the lipid subfamilies, suggesting some lipids as potential AD biomarkers. In addition, the estrous cycle monitoring could be relevant in female studies.</p>","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":null,"pages":null},"PeriodicalIF":7.9,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11323474/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141981516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
18F-FDG PET can effectively rule out conversion to dementia and the presence of CSF biomarker of neurodegeneration: a real-world data analysis. 18F-FDG PET 可有效排除痴呆症的转化和 CSF 神经变性生物标志物的存在:真实世界数据分析。
IF 7.9 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-08-13 DOI: 10.1186/s13195-024-01535-3
Sébastien Heyer, Maïa Simon, Matthieu Doyen, Ali Mortada, Véronique Roch, Elodie Jeanbert, Nathalie Thilly, Catherine Malaplate, Anna Kearney-Schwartz, Thérèse Jonveaux, Aurélie Bannay, Antoine Verger

Background: Precisely defining the delay in onset of dementia is a particular challenge for early diagnosis. Brain [18F] fluoro-2-deoxy-2-D-glucose (18F-FDG) Positron Emission Tomography (PET) is a particularly interesting tool for the early diagnosis of neurodegenerative diseases, through the measurement of the cerebral glucose metabolic rate. There is currently a lack of longitudinal studies under real-life conditions, with sufficient patients, to accurately evaluate the predictive values of brain 18F-FDG PET scans. Here, we aimed to estimate the value of brain 18F-FDG PET for predicting the risk of dementia conversion and the risk of occurrence of a neurodegenerative pathology.

Methods: Longitudinal data for a cohort of patients with no diagnosis of dementia at the time of recruitment referred by a tertiary memory clinic for brain 18F-FDG PET were matched with (Prince M, Wimo A, Guerchet Maëlenn, Ali G-C, Wu Y-T et al. World Alzheimer Report 2015. The Global Impact of Dementia: An analysis of prevalence, incidence, cost and trends. [Research Report] Alzheimer's Disease International. 2015. 2015.) data from the French National Health Data System (NHDS), (Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535-62.) data from the National Alzheimer Bank (NAB), and (Davis M, O`Connell T, Johnson S, Cline S, Merikle E, Martenyi F, et al. Estimating Alzheimer's Disease Progression Rates from Normal Cognition Through Mild Cognitive Impairment and Stages of Dementia. CAR. 2018;15(8):777-88.) lumbar puncture (LP) biomarker data. The criteria for dementia conversion were the designation, within the three years after the brain 18F-FDG PET scan, of a long-term condition for dementia in the NHDS and a dementia stage of cognitive impairment in the NAB. The criterion for the identification of a neurodegenerative disease in the medical records was the determination of LP biomarker levels.

Results: Among the 403 patients (69.9 ± 11.4 years old, 177 women) from the initial cohort with data matched with the NHDS data, 137 were matched with the NAB data, and 61 were matched with LP biomarker data. Within three years of the scan, a 18F-FDG PET had negative predictive values of 85% for dementia conversion (according to the NHDS and NAB datasets) and 95% for the presence of LP neurodegeneration biomarkers.

Conclusion: A normal brain 18F-FDG PET scan can help rule out the risk of dementia conversion and the presence of cerebrospinal fluid (CSF) biomarker of neurodegeneration early with high certainty, allowing modifications to patient management regimens in the short term.

Trial registration: Clinical Trials database (NCT04804722). March

背景:准确界定痴呆症发病的延迟时间是早期诊断的一项特殊挑战。脑[18F]氟-2-脱氧-2-D-葡萄糖(18F-FDG)正电子发射断层扫描(PET)通过测量脑葡萄糖代谢率,是早期诊断神经退行性疾病的一种特别有趣的工具。目前,还缺乏在真实条件下对足够多的患者进行纵向研究,以准确评估脑 18F-FDG PET 扫描的预测价值。在此,我们旨在估算脑 18F-FDG PET 对预测痴呆转化风险和神经退行性病变发生风险的价值:将招募时未确诊痴呆症的患者队列的纵向数据与一家三级记忆诊所转诊的脑18F-FDG PET数据进行比对(Prince M、Wimo A、Guerchet Maëlenn、Ali G-C、Wu Y-T et al.痴呆症的全球影响:对患病率、发病率、成本和趋势的分析。[研究报告] 阿尔茨海默病国际。2015.2015.) 数据来自法国国家健康数据系统 (NHDS),(Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework:NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.Alzheimers Dement.2018;14(4):535-62.) 数据来自国家阿尔茨海默病库(NAB),以及(Davis M, O`Connell T, Johnson S, Cline S, Merikle E, Martenyi F, et al. Estimating Alzheimer's Disease Progression Rates from Normal Cognition Through Mild Cognitive Impairment and Stages of Dementia.CAR.2018;15(8):777-88。)腰椎穿刺(LP)生物标志物数据。痴呆转换的标准是,在脑18F-FDG PET扫描后的三年内,在NHDS中被指定为痴呆长期病症,在NAB中被指定为痴呆认知障碍阶段。病历中确定神经退行性疾病的标准是确定 LP 生物标志物水平:在与 NHDS 数据相匹配的初始队列中的 403 名患者(69.9 ± 11.4 岁,177 名女性)中,137 人与 NAB 数据相匹配,61 人与 LP 生物标记物数据相匹配。扫描后三年内,18F-FDG PET 对痴呆症转化的阴性预测值为 85%(根据 NHDS 和 NAB 数据集),对 LP 神经变性生物标记物存在的阴性预测值为 95%:结论:正常的脑18F-FDG正电子发射计算机断层扫描可帮助早期排除痴呆转化的风险和存在脑脊液(CSF)神经变性生物标志物的高度确定性,从而在短期内修改患者管理方案:临床试验数据库(NCT04804722)。2021年3月18日。回顾性注册。
{"title":"<sup>18</sup>F-FDG PET can effectively rule out conversion to dementia and the presence of CSF biomarker of neurodegeneration: a real-world data analysis.","authors":"Sébastien Heyer, Maïa Simon, Matthieu Doyen, Ali Mortada, Véronique Roch, Elodie Jeanbert, Nathalie Thilly, Catherine Malaplate, Anna Kearney-Schwartz, Thérèse Jonveaux, Aurélie Bannay, Antoine Verger","doi":"10.1186/s13195-024-01535-3","DOIUrl":"10.1186/s13195-024-01535-3","url":null,"abstract":"<p><strong>Background: </strong>Precisely defining the delay in onset of dementia is a particular challenge for early diagnosis. Brain [<sup>18</sup>F] fluoro-2-deoxy-2-D-glucose (<sup>18</sup>F-FDG) Positron Emission Tomography (PET) is a particularly interesting tool for the early diagnosis of neurodegenerative diseases, through the measurement of the cerebral glucose metabolic rate. There is currently a lack of longitudinal studies under real-life conditions, with sufficient patients, to accurately evaluate the predictive values of brain <sup>18</sup>F-FDG PET scans. Here, we aimed to estimate the value of brain <sup>18</sup>F-FDG PET for predicting the risk of dementia conversion and the risk of occurrence of a neurodegenerative pathology.</p><p><strong>Methods: </strong>Longitudinal data for a cohort of patients with no diagnosis of dementia at the time of recruitment referred by a tertiary memory clinic for brain <sup>18</sup>F-FDG PET were matched with (Prince M, Wimo A, Guerchet Maëlenn, Ali G-C, Wu Y-T et al. World Alzheimer Report 2015. The Global Impact of Dementia: An analysis of prevalence, incidence, cost and trends. [Research Report] Alzheimer's Disease International. 2015. 2015.) data from the French National Health Data System (NHDS), (Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535-62.) data from the National Alzheimer Bank (NAB), and (Davis M, O`Connell T, Johnson S, Cline S, Merikle E, Martenyi F, et al. Estimating Alzheimer's Disease Progression Rates from Normal Cognition Through Mild Cognitive Impairment and Stages of Dementia. CAR. 2018;15(8):777-88.) lumbar puncture (LP) biomarker data. The criteria for dementia conversion were the designation, within the three years after the brain <sup>18</sup>F-FDG PET scan, of a long-term condition for dementia in the NHDS and a dementia stage of cognitive impairment in the NAB. The criterion for the identification of a neurodegenerative disease in the medical records was the determination of LP biomarker levels.</p><p><strong>Results: </strong>Among the 403 patients (69.9 ± 11.4 years old, 177 women) from the initial cohort with data matched with the NHDS data, 137 were matched with the NAB data, and 61 were matched with LP biomarker data. Within three years of the scan, a <sup>18</sup>F-FDG PET had negative predictive values of 85% for dementia conversion (according to the NHDS and NAB datasets) and 95% for the presence of LP neurodegeneration biomarkers.</p><p><strong>Conclusion: </strong>A normal brain <sup>18</sup>F-FDG PET scan can help rule out the risk of dementia conversion and the presence of cerebrospinal fluid (CSF) biomarker of neurodegeneration early with high certainty, allowing modifications to patient management regimens in the short term.</p><p><strong>Trial registration: </strong>Clinical Trials database (NCT04804722). March ","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":null,"pages":null},"PeriodicalIF":7.9,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11320856/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141970411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Protein intake and episodic memory: the moderating role of the apolipoprotein E ε4 status 蛋白质摄入量与外显记忆:载脂蛋白 E ε4 状态的调节作用
IF 9 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-08-12 DOI: 10.1186/s13195-024-01546-0
Musung Keum, Boung Chul Lee, Young Min Choe, Guk-Hee Suh, Shin Gyeom Kim, Hyun Soo Kim, Jaeuk Hwang, Dahyun Yi, Jee Wook Kim
This study investigated the correlation between protein intake and Alzheimer’s disease (AD)-related cognitive decline, particularly in episodic memory, among older adults without dementia. Furthermore, we assessed the moderating effect of apolipoprotein ε4 (APOE4) on this association and analyzed its influence on other cognitive functions beyond memory. The study involved 196 participants who underwent assessments for protein intake, cognitive performance, APOE4 genotyping, and nutritional biomarkers. Protein intake was categorized into low, medium, and high based on the consumption of dairy, legumes, eggs, meat, and fish. High protein intake was significantly associated with better episodic memory and overall cognition. Moreover, a significant interaction was found between high protein intake and APOE4, indicating that APOE4 moderates the association between high protein intake level and episodic memory. Sensitivity analysis confirmed these results among participants with stable food intake. Our study results demonstrated that high protein intake is associated with better episodic memory among older adults without dementia. Furthermore, the findings highlight the significant role of APOE4 status in moderating the relationship between protein consumption and episodic memory. These results suggest that dietary interventions focusing on protein intake could be beneficial for cognitive health, particularly in individuals with a genetic predisposition to AD.
本研究调查了蛋白质摄入量与阿尔茨海默病(AD)相关认知能力下降之间的相关性,尤其是在没有痴呆症的老年人中的外显记忆方面。此外,我们还评估了脂蛋白ε4(APOE4)对这种关联的调节作用,并分析了其对记忆以外的其他认知功能的影响。这项研究有 196 名参与者参加,他们接受了蛋白质摄入量、认知能力、APOE4 基因分型和营养生物标志物的评估。根据乳制品、豆类、鸡蛋、肉类和鱼类的摄入量,蛋白质摄入量被分为低、中和高。蛋白质摄入量高与记忆力和整体认知能力的提高有明显关系。此外,还发现高蛋白摄入量与 APOE4 之间存在明显的交互作用,这表明 APOE4 可调节高蛋白摄入量与外显记忆之间的关系。敏感性分析在食物摄入量稳定的参与者中证实了这些结果。我们的研究结果表明,在没有痴呆症的老年人中,高蛋白摄入量与更好的外显记忆有关。此外,研究结果还突显了 APOE4 状态在调节蛋白质摄入量与外显记忆之间关系中的重要作用。这些结果表明,以蛋白质摄入量为重点的膳食干预措施可能有益于认知健康,尤其是对有注意力缺失症遗传倾向的人。
{"title":"Protein intake and episodic memory: the moderating role of the apolipoprotein E ε4 status","authors":"Musung Keum, Boung Chul Lee, Young Min Choe, Guk-Hee Suh, Shin Gyeom Kim, Hyun Soo Kim, Jaeuk Hwang, Dahyun Yi, Jee Wook Kim","doi":"10.1186/s13195-024-01546-0","DOIUrl":"https://doi.org/10.1186/s13195-024-01546-0","url":null,"abstract":"This study investigated the correlation between protein intake and Alzheimer’s disease (AD)-related cognitive decline, particularly in episodic memory, among older adults without dementia. Furthermore, we assessed the moderating effect of apolipoprotein ε4 (APOE4) on this association and analyzed its influence on other cognitive functions beyond memory. The study involved 196 participants who underwent assessments for protein intake, cognitive performance, APOE4 genotyping, and nutritional biomarkers. Protein intake was categorized into low, medium, and high based on the consumption of dairy, legumes, eggs, meat, and fish. High protein intake was significantly associated with better episodic memory and overall cognition. Moreover, a significant interaction was found between high protein intake and APOE4, indicating that APOE4 moderates the association between high protein intake level and episodic memory. Sensitivity analysis confirmed these results among participants with stable food intake. Our study results demonstrated that high protein intake is associated with better episodic memory among older adults without dementia. Furthermore, the findings highlight the significant role of APOE4 status in moderating the relationship between protein consumption and episodic memory. These results suggest that dietary interventions focusing on protein intake could be beneficial for cognitive health, particularly in individuals with a genetic predisposition to AD.","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":null,"pages":null},"PeriodicalIF":9.0,"publicationDate":"2024-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141942644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The interrelationships of CSF sTREM2, AD pathology, minimal depressive symptoms, and cognition in non-demented adults. 非痴呆成人 CSF sTREM2、AD 病理学、轻度抑郁症状和认知能力之间的相互关系。
IF 7.9 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-08-10 DOI: 10.1186/s13195-024-01550-4
Xue Liu, Guang-Xiang Yu, Mei Xue, Liang-Yu Huang, Yan Fu, Zuo-Teng Wang, Lan Tan, Ya-Nan Ou

Background: Microglial activation has been suggested to be involved in the pathogenesis of depression and Alzheimer's disease (AD). Soluble triggering receptor expressed on myeloid cells 2 (sTREM2) is a marker of microglial activation. The purpose of this study was to investigate the interrelationships of cerebrospinal fluid (CSF) sTREM2, AD pathology, as well as minimal depressive symptoms (MDSs), and cognition.

Methods: A total of 545 non-demented individuals from the Alzheimer's Disease Neuroimaging Initiative cohort were included in our study. The average age of the total population was 72.6 years and the percentage of females was 42.6%. Linear regression models were conducted to investigate the linear relationships of MDSs with CSF sTREM2, AD pathology, cognition, and brain structure. Mediation models and structural equation models (SEM) were conducted to examine whether CSF sTREM2 mediated the relationships of MDSs with AD pathology and cognition.

Results: Results revealed that individuals with MDSs had lower CSF sTREM2 levels than normal controls. Linear regression showed that MDSs were linearly associated with CSF sTREM2 (PFDR = 0.012) and amyloid biomarkers (PFDR < 0.05), as well as cognitive scores (PFDR < 0.05) and hippocampal volume (PFDR = 0.003). Mediation analyses revealed that CSF sTREM2 mediated the association between MDSs and amyloid pathology, with the mediating proportions ranging from 6.030 to 18.894%. However, SEM failed to reveal that MDS affected cognition through CSF amyloid pathology and CSF sTREM2.

Conclusions: MDSs are associated with amyloid pathology and cognition. CSF sTREM2 may potentially be an intervenable target between depression and AD pathology.

背景:小胶质细胞活化被认为与抑郁症和阿尔茨海默病(AD)的发病机制有关。髓系细胞上表达的可溶性触发受体 2(sTREM2)是小胶质细胞活化的标志物。本研究的目的是探讨脑脊液(CSF)sTREM2、AD病理以及轻微抑郁症状(MDS)和认知能力之间的相互关系:我们的研究共纳入了阿尔茨海默病神经影像学倡议队列中的 545 名非痴呆患者。研究对象的平均年龄为 72.6 岁,女性占 42.6%。通过线性回归模型研究了MDS与CSF sTREM2、AD病理、认知和大脑结构的线性关系。通过中介模型和结构方程模型(SEM)研究 CSF sTREM2 是否对 MDSs 与 AD 病理和认知的关系起中介作用:结果显示,MDSs患者的CSF sTREM2水平低于正常对照组。线性回归显示,MDS与CSF sTREM2(PFDR = 0.012)和淀粉样蛋白生物标志物(PFDR < 0.05)以及认知评分(PFDR < 0.05)和海马体积(PFDR = 0.003)呈线性相关。中介分析显示,CSF sTREM2对MDS与淀粉样病理之间的关联起中介作用,中介比例从6.030%到18.894%不等。然而,SEM未能揭示MDS通过脑脊液淀粉样病理和脑脊液sTREM2影响认知:结论:MDS与淀粉样病理和认知相关。结论:MDS 与淀粉样病理和认知相关,脑脊液 sTREM2 可能是抑郁症和注意力缺失症病理之间的一个可干预靶点。
{"title":"The interrelationships of CSF sTREM2, AD pathology, minimal depressive symptoms, and cognition in non-demented adults.","authors":"Xue Liu, Guang-Xiang Yu, Mei Xue, Liang-Yu Huang, Yan Fu, Zuo-Teng Wang, Lan Tan, Ya-Nan Ou","doi":"10.1186/s13195-024-01550-4","DOIUrl":"10.1186/s13195-024-01550-4","url":null,"abstract":"<p><strong>Background: </strong>Microglial activation has been suggested to be involved in the pathogenesis of depression and Alzheimer's disease (AD). Soluble triggering receptor expressed on myeloid cells 2 (sTREM2) is a marker of microglial activation. The purpose of this study was to investigate the interrelationships of cerebrospinal fluid (CSF) sTREM2, AD pathology, as well as minimal depressive symptoms (MDSs), and cognition.</p><p><strong>Methods: </strong>A total of 545 non-demented individuals from the Alzheimer's Disease Neuroimaging Initiative cohort were included in our study. The average age of the total population was 72.6 years and the percentage of females was 42.6%. Linear regression models were conducted to investigate the linear relationships of MDSs with CSF sTREM2, AD pathology, cognition, and brain structure. Mediation models and structural equation models (SEM) were conducted to examine whether CSF sTREM2 mediated the relationships of MDSs with AD pathology and cognition.</p><p><strong>Results: </strong>Results revealed that individuals with MDSs had lower CSF sTREM2 levels than normal controls. Linear regression showed that MDSs were linearly associated with CSF sTREM2 (P<sub>FDR</sub> = 0.012) and amyloid biomarkers (P<sub>FDR</sub> < 0.05), as well as cognitive scores (P<sub>FDR</sub> < 0.05) and hippocampal volume (P<sub>FDR</sub> = 0.003). Mediation analyses revealed that CSF sTREM2 mediated the association between MDSs and amyloid pathology, with the mediating proportions ranging from 6.030 to 18.894%. However, SEM failed to reveal that MDS affected cognition through CSF amyloid pathology and CSF sTREM2.</p><p><strong>Conclusions: </strong>MDSs are associated with amyloid pathology and cognition. CSF sTREM2 may potentially be an intervenable target between depression and AD pathology.</p>","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":null,"pages":null},"PeriodicalIF":7.9,"publicationDate":"2024-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11316296/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141911298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction: Cholinesterase inhibitors and memantine are associated with a reduced mortality in nursing home residents with dementia: a longitudinal observational study. 更正:胆碱酯酶抑制剂和美金刚与养老院痴呆症患者死亡率的降低有关:一项纵向观察研究。
IF 7.9 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-08-05 DOI: 10.1186/s13195-024-01548-y
Charlotte Havreng-Théry, Bruno Oquendo, Victoria Zolnowski-Kolp, Pierre Krolak-Salmon, François Bertin-Hugault, Carmelo Lafuente-Lafuente, Joël Belmin
{"title":"Correction: Cholinesterase inhibitors and memantine are associated with a reduced mortality in nursing home residents with dementia: a longitudinal observational study.","authors":"Charlotte Havreng-Théry, Bruno Oquendo, Victoria Zolnowski-Kolp, Pierre Krolak-Salmon, François Bertin-Hugault, Carmelo Lafuente-Lafuente, Joël Belmin","doi":"10.1186/s13195-024-01548-y","DOIUrl":"10.1186/s13195-024-01548-y","url":null,"abstract":"","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":null,"pages":null},"PeriodicalIF":7.9,"publicationDate":"2024-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11302329/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141892652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Understanding machine learning applications in dementia research and clinical practice: a review for biomedical scientists and clinicians. 了解痴呆症研究和临床实践中的机器学习应用:面向生物医学家和临床医师的综述。
IF 7.9 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-08-01 DOI: 10.1186/s13195-024-01540-6
Yihan Wang, Shu Liu, Alanna G Spiteri, Andrew Liem Hieu Huynh, Chenyin Chu, Colin L Masters, Benjamin Goudey, Yijun Pan, Liang Jin

Several (inter)national longitudinal dementia observational datasets encompassing demographic information, neuroimaging, biomarkers, neuropsychological evaluations, and muti-omics data, have ushered in a new era of potential for integrating machine learning (ML) into dementia research and clinical practice. ML, with its proficiency in handling multi-modal and high-dimensional data, has emerged as an innovative technique to facilitate early diagnosis, differential diagnosis, and to predict onset and progression of mild cognitive impairment and dementia. In this review, we evaluate current and potential applications of ML, including its history in dementia research, how it compares to traditional statistics, the types of datasets it uses and the general workflow. Moreover, we identify the technical barriers and challenges of ML implementations in clinical practice. Overall, this review provides a comprehensive understanding of ML with non-technical explanations for broader accessibility to biomedical scientists and clinicians.

一些(国家间)纵向痴呆症观察数据集涵盖了人口统计学信息、神经影像学、生物标记物、神经心理学评估和突变组学数据,为将机器学习(ML)融入痴呆症研究和临床实践开创了一个新时代。机器学习能熟练处理多模态和高维数据,已成为促进早期诊断、鉴别诊断以及预测轻度认知障碍和痴呆症发病和进展的创新技术。在这篇综述中,我们将评估 ML 的当前和潜在应用,包括其在痴呆症研究中的历史、与传统统计学的比较、使用的数据集类型以及一般工作流程。此外,我们还指出了在临床实践中实施 ML 的技术障碍和挑战。总之,这篇综述提供了对 ML 的全面了解,并提供了非技术性的解释,使生物医学科学家和临床医生更容易理解。
{"title":"Understanding machine learning applications in dementia research and clinical practice: a review for biomedical scientists and clinicians.","authors":"Yihan Wang, Shu Liu, Alanna G Spiteri, Andrew Liem Hieu Huynh, Chenyin Chu, Colin L Masters, Benjamin Goudey, Yijun Pan, Liang Jin","doi":"10.1186/s13195-024-01540-6","DOIUrl":"10.1186/s13195-024-01540-6","url":null,"abstract":"<p><p>Several (inter)national longitudinal dementia observational datasets encompassing demographic information, neuroimaging, biomarkers, neuropsychological evaluations, and muti-omics data, have ushered in a new era of potential for integrating machine learning (ML) into dementia research and clinical practice. ML, with its proficiency in handling multi-modal and high-dimensional data, has emerged as an innovative technique to facilitate early diagnosis, differential diagnosis, and to predict onset and progression of mild cognitive impairment and dementia. In this review, we evaluate current and potential applications of ML, including its history in dementia research, how it compares to traditional statistics, the types of datasets it uses and the general workflow. Moreover, we identify the technical barriers and challenges of ML implementations in clinical practice. Overall, this review provides a comprehensive understanding of ML with non-technical explanations for broader accessibility to biomedical scientists and clinicians.</p>","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":null,"pages":null},"PeriodicalIF":7.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11293066/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141858766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between treatment with sacubitril/valsartan and the risk of Alzheimer’s disease: a clinical update 使用沙库比妥/缬沙坦治疗与阿尔茨海默病风险之间的关系:临床最新进展
IF 9 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-08-01 DOI: 10.1186/s13195-024-01547-z
Antoine Garnier-Crussard
Since 2014, sacubitril/valsartan (Entresto®) is widely prescribed for heart failure. Despite neprilysin inhibition’s benefits in heart failure, concerns about potential amyloid-beta (Aβ) accumulation and Alzheimer’s disease (AD) risk have persisted. This narrative review, a decade post-approval, evaluates the risk of amyloid pathology and neurocognitive disorders in long-term sacubitril/valsartan use. Clinical trials, real-world studies, and pharmacovigilance data do not indicate an increased risk of cognitive decline. In patients treated with sacubitril/valsartan blood-based amyloid biomarkers show perturbations, while neuroimaging biomarkers reveal no significant increase in amyloid load. Despite a theoretical risk of amyloid accumulation and AD under treatment with sacubitril/valsartan, current clinical data appears reassuring, and there is no signal indicating an increased risk of cognitive decline, but a perturbation of amyloid blood-based biomarkers, which implies great caution when interpreting biomarkers in this context.
自2014年以来,萨库比特利/缬沙坦(Entresto®)被广泛用于治疗心力衰竭。尽管肾酶抑制剂对心力衰竭有好处,但人们对潜在的淀粉样β(Aβ)积累和阿尔茨海默病(AD)风险的担忧一直存在。本叙述性综述在药物批准十年后对长期服用沙库比妥/缬沙坦的淀粉样病变和神经认知障碍风险进行了评估。临床试验、真实世界研究和药物警戒数据均未表明认知能力下降的风险会增加。在使用沙库比妥/缬沙坦治疗的患者中,血液中的淀粉样蛋白生物标志物显示出干扰,而神经影像生物标志物显示淀粉样蛋白负荷没有显著增加。尽管使用沙库比特利/缬沙坦治疗存在淀粉样蛋白积累和注意力缺失症的理论风险,但目前的临床数据似乎令人欣慰,没有信号表明认知能力下降的风险增加,但血液中基于淀粉样蛋白的生物标志物出现了扰动,这意味着在这种情况下解释生物标志物时要非常谨慎。
{"title":"Association between treatment with sacubitril/valsartan and the risk of Alzheimer’s disease: a clinical update","authors":"Antoine Garnier-Crussard","doi":"10.1186/s13195-024-01547-z","DOIUrl":"https://doi.org/10.1186/s13195-024-01547-z","url":null,"abstract":"Since 2014, sacubitril/valsartan (Entresto®) is widely prescribed for heart failure. Despite neprilysin inhibition’s benefits in heart failure, concerns about potential amyloid-beta (Aβ) accumulation and Alzheimer’s disease (AD) risk have persisted. This narrative review, a decade post-approval, evaluates the risk of amyloid pathology and neurocognitive disorders in long-term sacubitril/valsartan use. Clinical trials, real-world studies, and pharmacovigilance data do not indicate an increased risk of cognitive decline. In patients treated with sacubitril/valsartan blood-based amyloid biomarkers show perturbations, while neuroimaging biomarkers reveal no significant increase in amyloid load. Despite a theoretical risk of amyloid accumulation and AD under treatment with sacubitril/valsartan, current clinical data appears reassuring, and there is no signal indicating an increased risk of cognitive decline, but a perturbation of amyloid blood-based biomarkers, which implies great caution when interpreting biomarkers in this context.","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":null,"pages":null},"PeriodicalIF":9.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141873025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Alzheimer's Research & Therapy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1